kabutan

SymBio Pharmaceuticals Limited(4582) Summary

4582
TSE Growth
SymBio Pharmaceuticals Limited
99
JPY
-2
(-1.98%)
Dec 5, 11:30 am JST
0.63
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
99.5
Dec 5, 11:29 am JST
Summary Chart Historical News Financial Result
PER
PBR
4.08
Yield
ー%
Margin Trading Ratio
11,263.25
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
100 JPY 0.64 USD
Previous Close Dec 4
101 JPY 0.65 USD
High Dec 5, 9:05 am
101 JPY 0.65 USD
Low Dec 5, 9:00 am
99 JPY 0.63 USD
Volume
176,400
Trading Value
0.02B JPY 0.11M USD
VWAP
100.05 JPY 0.65 USD
Minimum Trading Value
9,900 JPY 63 USD
Market Cap
5.41B JPY 0.03B USD
Number of Trades
66
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
263
1-Year High Sep 17, 2025
3,139
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 4,002,400
Nov 21, 2025 0 4,009,700
Nov 14, 2025 0 4,348,900
Nov 7, 2025 0 4,282,600
Oct 31, 2025 0 4,356,600
Company Profile
SymBio Pharmaceuticals Limited specializes in three areas: cancer, hematology, and pain management. The company also commercializes new drug candidates from other companies.
Sector
Pharmaceuticals
SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on rare diseases, primarily in the fields of oncology, hematology, and viral infections. The company advances the development of compounds that have already established proof of concept in humans. Utilizing its unique discovery network and evaluation expertise, SymBio conducts initial screenings through its in-house specialist staff, followed by rigorous evaluations from experienced external experts before finalizing potential in-licensing candidates. By adopting a "labo-less fab-less" strategy to minimize fixed costs, the company concentrates on high-value-added activities while outsourcing routine development tasks. SymBio's pipeline includes drugs such as Treakisym, rigosertib, and brincidofovir, promoting new drug development in areas with high unmet medical needs. While the company has primarily focused its business operations in Japan and Asia, it now aims to expand globally to enhance its business value.